TP-317 Development Programs
| Indication | Stage | Supporting Data | Next Step |
|---|---|---|---|
| IBD: Ulcerative colitis | Phase 1b recruiting | Dose selection based on Phase 1a; proof of mechanism in colitis models | Phase 1b in moderate-to-severe UC (NCT07834515) |
| IBD: Crohn’s disease | Phase 1a complete | Effects on collagen cross-linking genes and collagen deposition in colitis models | Fibrosis biomarkers from the UC Phase 1b to inform Crohn’s development |
| Oncology: Solid tumors | Phase 1a complete | Single-agent and checkpoint-inhibitor combination activity in multiple tumor models (colorectal, lung, melanoma and pancreatic) | Available for partnering alongside the IBD program |
TP-317 is an investigational drug that has not been approved by the U.S. Food and Drug Administration.
Partner with Thetis
We welcome discussions with companies interested in TP-317 for IBD and oncology.